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OBJECTIVES: In July 2000, Florida replaced a Federal law man-
dating all motorcycle riders to wear helmets with a state law
requiring helmets only for those <21 years, or with under $10,000
health insurance. Hospitalizations for motorcycle accident-
related injuries prior to and after the law changed were examined
to understand potential consequences. METHODS: Florida 
hospital databases for 13 quarters prior to January 4, 1997–
June 30, 2000) and after the change July 1, 2000–Septemebr 30,
2003), and published Florida motorcycle crash statistics were
examined. Hospitalized cases with crash-related injuries were
identiﬁed by via Emergency Department, ICD-9 diagnosis and E
codes (E810.2-E825.2, E810.3-E825.3). Injury type, demo-
graphics, costs, length of stay (LOS) and disposition were ana-
lyzed. Charges (accommodations and ancillary services) adjusted
by a 0.46 cost-to-charge ratio and appropriate inﬂation indices
are reported as costs (2005 US$). RESULTS: In the pre-repeal
period, 3914 inpatient motorcycle-related injury cases were iden-
tiﬁed (males: 86%; mean age: 35.6, mean LOS: 6 days); 6424
cases in post-repeal period (males: 87%, mean age: 36.4, mean
LOS: 6 days); due to a rise in reported motorcycle crashes (33%),
all related-injuries (44%) and deaths (66%) during 1997–2003;
however, broader E-code use may also be a factor. Among 
hospitalized cases, there were signiﬁcantly (p < 0.01) more head,
neck and cervical spinal cord injuries (45% vs 35%), and deaths
(2.9% vs. 2.2%) post-repeal. Although average LOS did 
not increase, average cost per day ($4093 vs. $3359), and 
per stay ($20,502 vs. $17,243) increased signiﬁcantly (p < 0.01)
post-repeal. Cumulative cost of inpatient care for motorcycle-
related injuries rose from $68 million to $132 million during this
period. CONCLUSIONS:Since universal helmet requirements
were relaxed, there has been a substantial increase in motorcycle
accident-related injuries overall, head injury hospitalizations, and
injury-related deaths. Beyond clinical and societal consequences,
these increases reﬂect an increased economic burden as well.
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OBJECTIVES: To study the prevalence of erectile disorder in
males with chronic pain on opioids. Chronic pain can lead to
reduced quality of life and strain on relationships. Opioids them-
selves can lead to signiﬁcant side effects, including a reduction
in serum testosterone and interference in the hypothalamic—
pituitary-axis. METHODS: Male patients in an opioid clinic
with chronic pain on opioids were screened for erectile disorder.
RESULTS: Ninety ﬁve patients were screened and 27 patients
29%) were positive for the disorder. Only ten (37%) had
received treatment. CONCLUSIONS: Erectile disorder is an
under diagnosed and treated disorder in chronic pain patients on
opioids. Male patients with chronic pain should be routinely
screened for erectile disorders.
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OBJECTIVE: The objective of this study was to assess the impact
of back pain on absenteeism, productivity loss, and direct health
care costs using the Medical Expenditure Panel Survey (MEPS).
METHODS: Individuals between the ages of 18 and 65 years
who participated in the MEPS during 2000 were included in the
study. Back pain patients were identiﬁed using ICD-9 codes. The
predictors of absenteeism in individuals who experienced back
pain were identiﬁed using Zero-inﬂated negative binomial regres-
sion (ZINB). Absenteeism days due to back pain were estimated
based on the ZINB regression model. Productivity loss was esti-
mated using the human capital approach. RESULTS: In 2000,
the one-year period prevalence of back pain in individuals
between 18 and 65 years of age was 11.1%. About 16.3% of
the individuals who were employed and who reported back pain
experienced back pain due to work-related injuries. Ethnicity
and union contract were identiﬁed as signiﬁcant predictors of
likelihood of absenteeism in individuals who experienced back
pain. The signiﬁcant predictors of absenteeism rate were per-
ceived overall health status due to back pain, and ethnicity. The
mean number of absenteeism days due to back pain was esti-
mated to be six days and a total of nine million absenteeism days
were due to back pain. The total productivity loss due to back
pain-related absenteeism was estimated to be $3.6 billion and
the total direct health care costs was estimated to be $14 billion.
The average productivity loss due to back pain was estimated to
be $305 per person and the annual per-capita direct health care
cost due to back pain was $730. CONCLUSIONS: Back pain is
one of the most common and challenging problems in primary
care. The economic burden due to back pain is of concern to
employers, insurance agencies, policy decision makers and treat-
ment decision makers.
PAIN—Health Care Use & Policy
PPN3
THE PRICING AND DISTRIBUTION OF REPACKAGED DRUGS:
COST EFFECTS IN THE CALIFORNIA WORKERS’
COMPENSATION SYSTEM
Gitlin M1,Wilson L2
1University of California, San Francisco and Amgen, Inc, San Francisco,
CA, USA, 2University of California, San Francisco, San Francisco, CA,
USA
OBJECTIVE: The California Workers’ Compensation (WC)
drug pricing system effective in 2004 tied payments to the Medi-
Cal system, but 60% of National Drug Codes (NDC) in the WC
System lacked an equivalent Medi-Cal NDC; and many were
repackaged pharmaceuticals. A model of pharmaceutical distri-
bution and claims processing of repackaged pharmaceuticals was
deﬁned. We assessed the cost and utilization of repackaged phar-
maceuticals to determine potential lost savings to the California
WC system. METHODS: We used 2002 data from the Califor-
nia Workers’ Compensation Institute and Medi-Cal pharmacy
expenditures. We described the extent of lost savings due to
repackaged pharmaceuticals, compared the characteristics of
repackaged pharmaceuticals in the WC using ANOVA, and iden-
tiﬁed predictors of repackaged pharmaceuticals using GLM
regression. We also suggest alternative pricing systems for Medi-
Cal non-equivalent repackaged NDCs. RESULTS: Repackaged
pharmaceuticals represented 55% of the Medi-Cal non-
equivalent NDCs used, but only 21% of total WC costs
($8,494,297) were attributed to repackaged pharmaceuticals.
Approximately 88% of repackaged pharmaceutical costs were
for generic medications. Companies most commonly associated
with repackaged pharmaceutical costs were Southwood Phar-
maceuticals (33.1%) and Pharma Pac (31.7%). Overall, com-
